Optimi Health (OPTH)

Manufactures botanical psilocybin and finished psilocybin and MDMA capsules for regulated therapeutic-access and clinical-research programs. The Princeton, British Columbia platform brings cultivation, extraction, analytical testing, formulation, encapsulation, packaging, storage and export documentation under one controlled-substance operating system. Products are supplied to licensed importers, pharmacies, authorized prescribers, clinical-trial sponsors and research organizations rather than directly to patients.

Commercial prescription access is active in Australia, while Canadian supply follows the Special Access Program and other markets depend on clinical-trial or regulatory permissions. Execution rests on GMP production, Health Canada licences, secure storage, destination-country import authority and shipment-specific export permits. The pharmaceutical focus follows the wind-down of its nutraceutical operation.